Category: Pharma News

केंद्र D&C अधिनियम और नियमों के उल्लंघन के लिए e-Pharmacy के खिलाफ कार्रवाई करने का दायित्व SLAs पर डालता है|

The Central Government is taking a stand that the sale of medicines should strictly adhere to the provisions of the existing regulations and that the State Licensing Authorities (SLAs) are legally empowered to act against violations of the legal provisions….

NeuroOne रीढ़ की हड्डी उत्तेजना के लिए उपन्यास thin film paddle lead के प्रारंभिक पशु प्रत्यारोपण को पूरा करता है|

A medical technology business called NeuroOne Medical Technologies Corporation said that the first animal implant of its innovative thin-film paddle leads for spinal cord stimulation had been successfully completed. The devices are designed to treat individuals with numerous failed back…

Kuria Therapeutics ने कॉर्नियल एंडोथेलियल disease के लिए topical Nrf2 activator के लिए USFDA Pre-IND परामर्श पूरा किया

The FDA provided encouraging input on Kuria Therapeutics’ development plan for KTX-1161 for corneal endothelial dysfunction during a pre-Investigational New Drug (IND) interaction, according to the pharmaceutical company, which is working on innovative ophthalmic and dermal treatments. A topical ophthalmic…

1948 के फार्मेसी अधिनियम के साथ फार्मेसियों के अनुपालन की जांच के लिए NSPC द्वारा तीन फार्मेसी निरीक्षकों की नियुक्ति की जाएगी।

The three district pharmacy officers who were chosen will soon receive appointment orders from the Nagaland State Pharmacy Council (NSPC) appointing them as pharmacy inspectors. Three inspectors will first be hired to inspect pharmacies for compliance with the Pharmaceutical Act…

एक अभिनव Stem Cell Robot जिसका UK MHR परीक्षण कर रहा है, जीवन रक्षक सेल उपचारों की पहुंच में क्रांति ला सकता है

The UK Medicines and Healthcare products Regulatory Agency is testing the CellQualia Intelligent Cell Processing System, a novel robotic robot that cultivates stem cells (MHRA). This robotic technology has the potential to offer patients with a variety of ailments safer…

Merck gives an update from the phase 2 KeyVibe-002 trial of MK-7684A, a coformulation of vibostolimab with pembrolizumab, in patients with metastatic NSCLC who have already received treatment.

The open-label portion of the non-registrational phase 2 KeyVibe-002 trial received an update from Merck, also known as MSD outside of the United States and Canada. For the treatment of patients with metastatic non-small cell lung cancer (NSCLC) who have…

Back to top
WhatsApp Join Telegram